Startup profile · funding coverage
Tmunity Therapeutics funding, valuation and investors
T-cell immunotherapy biotech (acquired by Instil Bio 2022).
Keep track of Tmunity Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
acquired
acquired
Overview
Tmunity Therapeutics developed next-generation T-cell immunotherapies, spun out of University of Pennsylvania research associated with CAR-T pioneers. The company advanced engineered T-cell programs for oncology. In 2022, Instil Bio acquired Tmunity in an all-stock deal to expand its cell therapy pipeline. Andreessen Horowitz participated in Tmunity's venture rounds as part of its bio portfolio.
Why Tmunity Therapeutics is interesting
Tmunity carried Penn cell-therapy science toward clinic — a16z bio bet consolidated when Instil Bio bought the platform for solid-tumor CAR-T expansion.
Product & use cases
Tmunity engineered T-cell therapies for cancer — building on academic CAR-T research toward clinical programs before Instil Bio acquisition.
- Oncology patients in cell therapy clinical trials (pre/post acquisition)
- Instil Bio pipeline expansion via Tmunity assets
- Academic-to-biotech translation of Penn immunotherapy science
Key facts
- Acquired by Instil Bio (2022) in all-stock deal
- a16z portfolio biotech company
- Penn-associated T-cell immunotherapy programs
- Part of cell therapy sector consolidation
Investors in our directory
Funds linked from Tmunity Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Deep Penn research lineage in cell therapy — scientific credibility in crowded CAR-T field.
Cell therapy remains clinically powerful but commercially and manufacturing-heavy; Tmunity's acquisition reflects consolidation of academic spinouts into larger platforms.
-
Novartis / Kite CAR-T incumbent
Commercial CAR-T products.
-
Allogene / off-the-shelf cell therapy adjacent
Allogeneic approaches vs autologous.
-
Instil Bio (acquirer) direct
Combined entity post-acquisition.
Notable stories
- Tmunity's Instil Bio acquisition continued the pattern of CAR-T startups combining to share manufacturing and clinical infrastructure costs (2022 press).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Tmunity Therapeutics's financing or category context.
FAQs about Tmunity Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.